Posted on 3/22/18
Tekla Healthcare Investors Announce Renewal of Share Repurchase Program
BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the . . .
Posted on 3/22/18
Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC
WALTHAM, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative . . .
Posted on 3/21/18
Regeneron and Alnylam Pharmaceuticals Announce Collaboration
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced a collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis . . .
Posted on 3/21/18
Symbiotix Biotherapies Announces License Agreement with Harvard University
BOSTON--(BUSINESS WIRE)--Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into . . .
Posted on 3/21/18
Eleven Biotherapeutics Prices $10.0 Million Offering Priced At-the-Market
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that it has . . .
Posted on 3/21/18
Prominent Physical Therapy Provider in Massachusetts Makes Servicing Suburban Communities a Top Priority
Professional Physical Therapy, a leading private, outpatient physical therapy provider in the Northeast, is pleased to announce the opening of its newest state-of-the-art clinic in Winchester, . . .
Posted on 3/21/18
Boston Scientific To Acquire NxThera
Boston Scientific (BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed . . .
Posted on 3/20/18
Homology Medicines On Deck For IPO
Bedford, MA-based Homology Medicines (Pending:FIXX) is set for its IPO of ~6.7M shares of common stock at $14 - 16.The company develops genetic medicines based on . . .
Posted on 3/20/18
Biogen's Key Variable: Its Neuroscience Pipeline
Biogen (NASDAQ:BIIB) is best known for its MS (multiple sclerosis) therapies. While Biogen is set to remain a major player in that setting, its future expansion . . .
Posted on 3/19/18
Eloxx Pharmaceuticals Provides Business Update
WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to . . .
Posted on 3/18/18
Corindus Announces $25M Private Placement of Series A Convertible Preferred Shares and Warrants
WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has entered into definitive agreements to . . .
Posted on 3/18/18
CVS Pharmacy Now Offering New Shingles Vaccine at Locations Nationwide
CVS Pharmacy, the retail division of CVS Health (NYSE: CVS), announced today that all of its more than 9,800 pharmacies have the new Shingrix vaccine available . . .
Posted on 3/15/18
Cigna Deal - Not The Right Move
Health insurer Cigna Corp. (CI) announced that it has agreed to acquire U.S.-based pharmacy benefit manager (PBM) company Express Scripts (ESRX) for a total consideration of . . .
Posted on 3/15/18
Cigna Joins the Consolidation Parade With Bid to Buy Express Scripts
In this segment of the Motley Fool Money podcast, host Chris Hill is joined by Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's . . .
Posted on 3/15/18
Is Biogen Inc. a Buy?
Wall Street thinks pretty highly of Biogen Inc. (NASDAQ:BIIB). Of 32 analysts covering the biotech who were surveyed by Thomson Reuters, eight rated Biogen as a . . .
Posted on 3/14/18
Exosome Diagnostics Partners with Intezyne
Boston, MA, March 14, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a market leader in liquid biopsy and the world’s first exosome-based diagnostics company announces a collaboration . . .
Posted on 3/14/18
Cigna Joins the Consolidation Parade With Bid to Buy Express Scripts
In this segment of the Motley Fool Money podcast, host Chris Hill is joined by Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's . . .
Posted on 3/14/18
Why Biogen Stock Slumped in February
What happenedBiogen (NASDAQ:BIIB), a leader in the treatment of neurological and neurodegenerative diseases, saw its shares sink by a noteworthy 16.5% last month, according to S&P . . .
Posted on 3/13/18
PAREXEL and CHA Medical Group Partner
BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical development . . .
Posted on 3/12/18
OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, . . .
Posted on 3/12/18
Arch Therapeutics Provides Update on 510(k)
FRAMINGHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care . . .
Posted on 3/12/18
VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced . . .
Posted on 3/12/18
BioXcel Therapeutics Closes IPO
BRANFORD, Conn., March 12, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next . . .
Posted on 3/12/18
Merrimack Provides Business Update and Reports 2017 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2017 financial results for the . . .
Posted on 3/12/18
Biogen To Acquire Mid-Stage Asset From Pfizer For $590M
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-04958242, a first-in-class

